Loading...
Bilateral Trade Intelligence · $12 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $12 worth of pharmaceutical formulations from Bahrain across 5 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are BAHRAINI INTERNATIONAL MEDICINE MANUFACTURING COMP ($12). The leading products are Melatonin ($5) and Vitamin ($5). Average shipment value: $2.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Melatonin | $5 | 40.0% |
| 2 | Vitamin | $5 | 40.0% |
| 3 | Zinc | $2 | 20.0% |
India imports 3+ pharmaceutical formulations from Bahrain with a combined trade value of $12. Key products include Melatonin ($5), Vitamin ($5), Zinc ($2). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 5 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Bahrain, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Bahrain buyers, regulatory requirements, and logistics for that specific product corridor. Products include Melatonin ($5), Vitamin ($5), Zinc ($2) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Bahrain. Leading exporters include Bahraini International Medicine Manufacturing Comp, . The top exporter accounts for 100.0% of total India–Bahrain pharma exports. Source: Indian Customs (DGFT).
1 companies in Bahrain import pharmaceutical formulations from India. Top buyers include Auriga Research Private Limited, . The largest buyer accounts for 100.0% of India–Bahrain pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Bahrain and India has experienced modest activity from 2022 to 2026. In 2022, India imported pharmaceutical products valued at $12 USD from Bahrain, comprising five shipments. This consistent trade pattern indicates a stable, albeit limited, exchange in pharmaceutical goods between the two nations. The average shipment value stood at $2 USD, reflecting the niche nature of this trade route.
Bahrain's pharmaceutical exports to India are primarily concentrated in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The top three products imported by India from Bahrain during this period were melatonin, vitamins, and zinc supplements, accounting for 40%, 40%, and 20% of the total import value, respectively. This suggests a targeted export strategy by Bahrain, focusing on specific therapeutic areas that align with India's market needs.
Bahrain's contribution to India's pharmaceutical imports remains relatively small, with a total import value of $12 USD over the 2022-2026 period. This positions Bahrain as a minor supplier in India's diverse pharmaceutical import landscape. The imports from Bahrain are concentrated in specific product categories, notably melatonin, vitamins, and zinc supplements, indicating a strategic focus on these segments. The limited volume suggests that Bahrain's pharmaceutical industry is still in the early stages of penetrating the Indian market, with potential for growth as trade relations develop.
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Bahrain specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) in India has maintained its existing regulatory framework for foreign pharmaceutical imports, ensuring consistent standards for product safety and efficacy. Similarly, Bahrain's National Drug Regulatory Authority continues to uphold WHO-GMP standards for pharmaceutical manufacturing. While both countries have engaged in broader trade discussions, these have not yet translated into substantial shifts in the pharmaceutical trade corridor.
Registration process, GMP requirements, import documentation
For Bahraini pharmaceutical companies aiming to export products to India, obtaining approval from the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The registration process involves several key steps:
1. Application Submission: Companies must register on the CDSCO's SUGAM portal, providing detailed information about the applicant and the products intended for import.
2. Document Submission: Essential documents include the Certificate of Pharmaceutical Product (COPP), Good Manufacturing Practice (GMP) certificate, and a free sale certificate from the country of origin.
3. Product Approval: CDSCO evaluates the safety, efficacy, and quality of the pharmaceutical products. This may involve site inspections and assessments of manufacturing processes.
4. Import License Issuance: Upon successful evaluation, CDSCO grants an import license, authorizing the company to import and distribute the pharmaceutical products in India.
The entire process can take several months, depending on the complexity of the products and the completeness of the submitted documentation.
India requires that foreign pharmaceutical manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Bahraini manufacturers must obtain a GMP certificate from their national regulatory authority, confirming compliance with these standards. Additionally, CDSCO may conduct inspections of foreign manufacturing facilities to verify adherence to GMP guidelines. This ensures that imported pharmaceutical products meet India's stringent quality and safety requirements.
To import pharmaceutical products into India, Bahraini companies must prepare and submit the following documentation:
Ensuring all documentation is accurate and complete is crucial for the smooth importation of pharmaceutical products into India.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical imports from Bahrain are predominantly focused on specific product categories:
These categories indicate a strategic focus by Bahraini exporters on products that address prevalent health concerns in India, such as sleep disorders, nutritional deficiencies, and immune health.
The pharmaceutical products imported from Bahrain to India, including melatonin, vitamins, and zinc supplements, are not unique to Bahrain and are available from various global suppliers. However, Bahrain's adherence to WHO-GMP standards and its regulatory framework may offer a level of assurance regarding product quality and safety. While these products are not classified as innovative or specialty drugs, their consistent quality and compliance with international standards can be appealing to Indian consumers seeking reliable health supplements.
The demand for pharmaceutical imports from Bahrain to India is influenced by several factors:
These factors collectively contribute to the sustained, albeit limited, demand for pharmaceutical imports from Bahrain to India.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes:
These duties and taxes are subject to change based on government policies and international trade agreements.
As of March 2026, there are no specific free trade agreements (FTAs) between India and Bahrain that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations but does not include specific provisions for pharmaceutical products between them. Any future trade agreements or negotiations may influence the tariff structure and import dynamics.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. This can impact the availability of generic versions of pharmaceutical products. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines in India, including imported drugs, to ensure affordability. Imported pharmaceutical products are subject to price controls, which can affect their market competitiveness compared to domestically produced alternatives.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Bahrain to India are typically transported via sea routes, given the geographical proximity and established maritime trade routes. The transit time for sea shipments from Bahrain to major Indian ports, such as Mumbai and Chennai, ranges from 7 to 14 days, depending on the shipping line and specific port operations. Air freight is also an option, with transit times of approximately 3 to 5 days, though this is less commonly used due to higher costs. The reliability of these routes is generally high, with established shipping schedules and protocols for pharmaceutical goods.
India exported pharmaceuticals worth $12 to Bahrain across 5 verified shipments.
1. BAHRAINI INTERNATIONAL MEDICINE MANUFACTURING COMP — $12. Total: 1 suppliers.
1. AURIGA RESEARCH PRIVATE LIMITED — $12. 1 buyers total.
1. Melatonin ($5, 40.0%); 2. Vitamin ($5, 40.0%); 3. Zinc ($2, 20.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $12 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$2 per consignment across 5 shipments.
1 Indian companies. Largest: BAHRAINI INTERNATIONAL MEDICINE MANUFACTURING COMP with $12.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 5 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists